Some very important IP developments took place early this month. Anubha blogged about the Regional Comprehensive Economic Partnership (RCEP) and how Japan is pushing for TRIPS plus commitment in the RCEP negotiation rounds. If this is accepted, it would be a great setback to India’s generic medicines industry. Thomas analysed a recent order passed by the Competition Commission of India wherein the CCI fined automobile manufacturers (including Tata Motors and Maruti Suzuki) for indulging in anti-competitive practices during sale of...
↧